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Here, we demonstrate that protein-coding RNA tran-
scripts can crosstalk by competing for common
microRNAs, with microRNA response elements as
the foundation of this interaction. We have termed
such RNA transcripts as competing endogenous
RNAs (ceRNAs). We tested this hypothesis in the
context of PTEN, a key tumor suppressor whose
abundance determines critical outcomes in tumori-
genesis. By a combined computational and experi-
mental approach, we identified and validated endog-
enous protein-coding transcripts that regulate
PTEN, antagonize PI3K/AKT signaling, and possess
growth- and tumor-suppressive properties. Notably,
we also show that these genes display concordant
expression patterns with PTEN and copy number
loss in cancers. Our study presents a road map for
the prediction and validation of ceRNA activity and
networks and thus imparts a trans-regulatory func-
tion to protein-coding mRNAs.INTRODUCTION
Regulation of gene expression by small noncoding RNA mole-
cules is ubiquitous in many eukaryotic organisms from protozoa
to plants and animals. In mammals, 22 nucleotide long RNAs
termed microRNAs guide the RNA-induced silencing complex
(RISC) to microRNA response elements (MREs) on target
transcripts, usually resulting in degradation of the transcript or
inhibition of its translation (Bartel, 2009; Bartel and Chen,
2004). Individual genes often contain MREs for multiple distinct344 Cell 147, 344–357, October 14, 2011 ª2011 Elsevier Inc.microRNAs, and conversely, individual microRNAs often target
multiple distinct transcripts (Friedman et al., 2009).
We and others recently provided experimental support to the
hypothesis that RNA molecules that share MREs can regulate
each other by competing for microRNA binding (Cazalla et al.,
2010; Jeyapalan et al., 2011; Kloc, 2008; Lee et al., 2009;
Poliseno et al., 2010b; Seitz, 2009). Specifically, we reported
several examples of pseudogene transcripts exerting regulatory
control of their ancestral cancer gene’s expression levels by
competing for microRNAs that targeted sequences common to
the mRNA and the pseudo-mRNA (Poliseno et al., 2010b), in
keeping with the notion that the microRNA activity should be
theoretically affected by the availability of its target MRE in the
cellular milieu (Arvey et al., 2010).
This, in turn, led us to hypothesize that the mRNA/microRNA
network would operate through a reverse logic whereby
protein-coding and noncoding mRNAs would communicate
with each other in a microRNA-dependent manner through
a MRE language (Salmena et al., 2011). We proposed that a
reversed RNA/microRNA function exists, whereby RNAs
actively regulate each other through direct competition for
microRNA binding. In this work, we tested this hypothesis
experimentally and present a comprehensive scheme for the
prediction and validation of ceRNA activity and networks
demonstrating that bioinformatic predictions followed by a set
of stringent biological tests allow for the identification and valida-
tion of ceRNAs for mRNAs of interest. We focused our analysis
on the ceRNA network encompassing PTEN, a critical tumor
suppressor gene that encodes a phosphatase that converts
phosphatidylinositol 3,4,5-trisphosphate to phosphatidylinositol
4,5-bisphosphate, thereby antagonizing the highly oncogenic
PI3K/Akt-signaling pathway (Hollander et al., 2011).
PTEN was selected as a model system for three reasons: (1)
PTEN expression is frequently altered in a wide spectrum of
human cancers (Hollander et al., 2011), (2) subtle changes in
PTEN dose dictate critical outcomes in tumor initiation and
progression in vivo (Alimonti et al., 2010; Berger et al., 2011;
Trotman et al., 2003), and (3) numerous microRNAs have
beenvalidatedasPTENregulators, including theproto-oncogenic
miR-106b25 cluster that is overexpressed in prostate cancer
(Huse et al., 2009; Mu et al., 2009; Olive et al., 2009; Poliseno
et al., 2010a; Xiao et al., 2008). Taken together, these previous
studies suggested that bona fide PTEN ceRNAs, as well as
a broader PTEN ceRNA network, may represent a previously un-
characterized RNA-dependent tumor-suppressive dimension.
RESULTS
Identification of Candidate PTEN ceRNAs
To identify and characterize the PTEN ceRNA network in the
human genome, we devised a multifaceted scheme involving
integrated computational analysis and experimental validation
(Figure 1A), an approach that we termed mutually targeted
MRE enrichment (MuTaME). Initially, we sought to identify
mRNAs that are targeted by PTEN-targeting microRNAs. We
focused on validated PTEN-targeting microRNAs, specifically
those previously implicated in the ceRNA-mediated regulation
of PTEN by its pseudogene PTENP1: miR-17-5p, miR-19a,
miR-19b, miR-20a, miR-20b, miR-26a, miR-26b, miR-93, miR-
106a, miR-106b, and miR-214 (Poliseno et al., 2010a, 2010b),
and we excluded miR-214 from subsequent analysis, as it is
not expressed in the cell lines utilized to validate the putative
PTEN ceRNAs (Figure S1A available online).
Importantly, we also examined the physical association of the
PTEN 30UTR with endogenous levels of these microRNAs in the
cell line used in our study. We reasoned that this represents a
critical selective criterion to guide the computational component
of our analysis (Figure 1A). To do so, we performed RNA immu-
noprecipitation (RIP) to pull down endogenous microRNAs
associated with the PTEN 30UTR (Figure S1B) and demonstrated
via real-time PCR analysis that the PTEN 30UTR RIP in DU145
prostate cancer cells significantly enriched for miR-17-5p,
19a, 19b, 20a, 26a, 93, 106a, and 106b compared to empty
vector and IgG controls and a nontargeting microRNA control
(miR-191) (Figure 1B). These results further support the claim
that these microRNAs, which were previously validated mainly
by overexpression and/or knockdown experiments, are bona
fide PTEN-targeting microRNAs in this cell line and justify their
inclusion in our analyses.
We next used the rna22 microRNA target prediction algorithm
(Miranda et al., 2006) available at http://cbcsrv.watson.ibm.com/
rna22.html to generate MuTaME scores for the entire human
protein-coding transcriptome. The choice of rna22 was based
on earlier reports supporting its low rate of false prediction
(Hammell et al., 2008; Ritchie et al., 2009). A central tenet of
our hypothesis is that trans-regulatory ceRNA crosstalk
increases with the number of microRNAs that are shared by tran-
scripts. This is the first consideration in deriving a MuTaMe
score. The second consideration results from an often ignored
dependence on the length of the candidate transcript’s 30UTR:
the expected number of spurious microRNA target predictions
increases with the length of the candidate 30UTR through
a nonlinear relationship (Altschul et al., 1990; Miranda et al.,2006), and this holds true independently of the algorithm used
to predict microRNA targets. This dependence on length and
the findings described in Miranda et al. and Ritchie et al.
(Miranda et al., 2006; Ritchie et al., 2009) suggest that scenarios
in which (1) there are many predicted MREs in a candidate tran-
script, (2) the MREs are spread over a relatively short span and
are as evenly distributed within the span as possible, and (3)
multiple MREs are predicted for each of the microRNAs under
consideration ought to be favored.
To summarize,MuTaMEevaluatesacandidateceRNAXbased
on the following: (1) how many microRNAs it shares with the
mRNA M of interest. In our case, this is PTEN and is captured
by the ratio of #microRNAs predicted to target X over
#microRNAs being considered, which increases with the number
of targeting microRNAs that X shares with M; (2) the number of
MREs predicted in X for the i-th microRNA and the width of
the span that they cover. This is captured by the ratio of #MREs
in X for i-th microRNA over distance between leftmost and
rightmost predicted MRE for the i-th microRNA, which favors
situations in which more MREs spanning shorter distances are
predicted for the i-th microRNA, and it captures one of the main
observations in (Ritchie et al., 2009); (3) how evenly distributed
the predicted MREs for the i-th microRNA are over the distance
they span in X. This is captured by the ratio of square of the
distance between leftmost and rightmost predicted MRE for the
i-th microRNA over sum of the squared distances between
successiveMREs of the i-thmicroRNA, which favorsmore evenly
distributed MREs for each microRNA and penalizes cases in
which the majority, but not all, of a microRNA’s MREs aggregate
in a narrow neighborhood; and (4) the relation between the total
number of MREs predicted in X compared to the total number
of microRNAs that give rise to these MREs. This is captured
by the ratio of (#MREs in X for all considered microRNAs 
#microRNAs predicted to target X + 1) over #MREs in X for all
considered microRNAs, which favors situations in which each
targetingmicroRNAgives rise tomore thanoneMRE inX. A priori,
there is no reason to favor one type of contribution more than the
rest, and thus, each candidate transcript X receives a com-
bined MuTaMe score obtained simply by multiplying these four
components. Furthermore, for our specific setting, we set strin-
gent criteria and required that (1) a candidate ceRNA be targeted
by at least seven of the ten validated PTEN-targeting microRNAs
and (2) all predicted MREs occur only in the candidate ceRNA’s
30UTR. One potential concern here is whether this scoring
approach would be biased in favor of transcripts X with longer
30UTRs. Notably, we observed no correlation between 30UTR
lengthandMuTaMescore (corr =0.13) or between30UTR length
and the number of microRNAs predicted to target a candidate
ceRNA (corr = 0.07). UsingMuTaMe, we identified 158 candidate
protein-coding transcripts representing 136 distinct genes as
putative trans-regulators of PTEN (Figures 1C and 1D and Table
S1). Intriguingly, the candidates displayed a nonrandom enrich-
ment in selected biological categories (Figure S1C).
Putative PTEN ceRNAs Are Coexpressed with PTEN
In Vivo
As our hypothesis predicts that transcripts within a ceRNA
network are coregulated, we first examined whether putativeCell 147, 344–357, October 14, 2011 ª2011 Elsevier Inc. 345
Figure 1. Mutually Targeted MRE Enrichment Analysis Predicts Competitive Endogenous RNAs for PTEN
(A) Schematic outlining the mutually targeted MRE enrichment (MuTaME) analysis and subsequent experimental validation strategy. Validated PTEN-targeting
microRNAs were used to predict putative PTEN ceRNAs. Candidates sharing at least seven microRNAs were considered putative PTEN ceRNAs.
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PTEN ceRNAs are coexpressed with PTEN in human samples.
We selected the top seven candidates from our MuTaME
analysis (NCOA7, BCL11B, SERINC1, ZNF460, NUDT13,
DTWD2, and VAPA) (Figure 1D) and investigated whether their
expression correlated with PTEN expression in human prostate
cancer (GSE21032) and glioblastoma (GSE15824), malignancies
commonly defined by reduced PTEN levels. Significantly,
NCOA7, SERINC1, ZNF460, and VAPA showed differential
expression when samples were subdivided according to PTEN
expression levels in both prostate cancer (179 total samples:
29 normal, 150 tumor) and glioblastoma (45 total samples: 5
normal, 40 tumor) (Figures 2A, 2B, and S2A). Expression of these
four genes was also significantly correlated with PTEN transcript
levels (Figure S2C).
As the prostate cancer study contained integrated expression
profiling of both mRNAs and microRNAs, we were also able to
rank patient samples according to microRNA expression levels.
This enabled us to assess whether microRNA expression levels
impact the coexpression correlation of PTEN ceRNAs andPTEN.
Taking into account only the expression levels of the ten vali-
dated PTEN-targeting microRNAs used in our analysis, we sub-
divided samples into two groups: the first in which microRNAs
were expressed at a lower level compared to their expression
level in all samples and the second in which they were expressed
at a higher level. The Pearson correlation coefficients between
PTEN and its candidate ceRNAs were calculated in both groups,
and intriguingly, we found an increase in correlation between
SERINC1, ZNF460, and VAPA expression levels and PTEN
when the microRNA expression was taken into consideration
(Figure 2C). NCOA7 was not significantly correlated with PTEN
in this analysis (Figure S2B).
The significant correlation between PTEN expression and
SERINC1, ZNF460, and VAPA expression and the sensitivity of
this correlation to microRNA expression levels support our
hypothesis that ceRNA transcripts can regulate PTEN levels in
a biologically relevant manner. We next examined the coexpres-
sion of these three genes with PTEN in a database of multitissue
and tissue-specific conserved human-mouse gene coexpres-
sion networks (Piro et al., 2011) and found that these genes
were present in the top 1% of genes coexpressed with PTEN
in several human-specific coexpression networks (Figure S2E).
Based on their consistent coexpression with PTEN, we selected
SERINC1, ZNF460, and VAPA for subsequent experimental
validation.
Additionally, to investigate the extent to which lower-ranking
candidates from our list exerted regulatory control over PTEN,
we first explored the correlation of the 20 transcripts on our list
with the lowest MuTaME scores with PTEN as described above.
One of the most significantly correlated transcripts in both the
prostate cancer and glioblastoma data sets was CNOT6L, which
was also found to be significantly correlated with PTEN in the
largest number of multitissue and tissue-specific conserved(B) MS2-RIP followed by microRNA RT-PCR to detect microRNAs endogenously
(C) Heat map showing MRE enrichment of the top 20 (top) and bottom 20 (midd
(D) Table summarizing predicted MREs in the 30UTRs of the top seven putative P
See also Figure S1 and Table S1.human-mouse gene coexpression networks (Figure S2D). We
thusselected it asanothercandidate for further validationanalysis.
PTEN ceRNAs Modulate PTEN Levels
We investigated the ability of these putative PTEN ceRNAs to
modulate PTEN levels by first examining the effect of depletion
of these candidates on endogenous PTEN protein levels in
DU145 prostate cancer cells (Figure 3A). For this analysis, we
also included two genes, ACSL4 and UNC5CL, which are
not predicted targets of these PTEN-targeting microRNAs
as negative controls (Figure 1C). These experiments were per-
formed using siRNA pools (a combination of four independent
siRNAs), which are designed to achieve strong on-target gene
knockdown with minimal off-target effects. Real-time PCR anal-
ysis confirmed efficient siRNA-mediated knockdown of candidate
PTEN ceRNAs (Figure S3A). Depletion of SERINC1, ZNF460,
VAPA, or CNOT6L transcripts did indeed result in a significant
reduction in PTEN protein levels, whereas depletion of ACSL4 or
UNC5CL did not have a significant effect (Figures 3A and 3B).
Moreover, reduced PTEN protein levels were accompanied by
a concomitant, albeit less significant, decrease in PTEN transcript
levels for SERINC1, VAPA, and CNOT6L knockdown (Figure 3B).
To ascertain whether this observed effect is dependent upon
regulation of the PTEN 30UTR, we constructed a chimeric lucif-
erase construct tagged with the PTEN 30UTR (Luc-PTEN30UTR).
This approach allows us to uncouple regulation of PTEN via
30UTR-targeting microRNAs from PTEN mRNA transcription
and protein stability. siRNA-mediated reduction of SERINC1,
VAPA, and CNOT6L transcripts in Luc-PTEN30UTR-expressing
cells significantly lowered luciferase activity (Figure 3C).
However, siRNA-mediated ZNF460 knockdown did not signifi-
cantly reduce Luc-PTEN30UTR activity, suggesting that the
observed effect on PTEN protein is not solely mediated by the
PTEN 30UTR. We thus excluded it from subsequent analysis.
Conversely, ectopic overexpression of PTEN ceRNA 30UTRs
in DU145 cells led to a marked upregulation of both Luc-
PTEN30UTR and endogenous protein levels, similar to the effect
of overexpression of the PTEN 30UTR on PTEN protein levels
(Figures 3D–3F). Due to their large size, the VAPA and CNOT6L
30UTRswere each cloned as two separate fragments subdivided
based on the location of predicted MREs. Thus, sequestration of
only a fraction of PTEN-targeting microRNAs may impact PTEN
expression.
MicroRNA Dependency of ceRNA-Mediated PTEN
Regulation
To investigate the microRNA dependency of ceRNA-mediated
PTEN regulation, we utilized isogenic wild-type and DICER
mutant HCT116 colon carcinoma cells. In the latter, gene target-
ing was used to disrupt a well-conserved segment of the
N-terminal helicase domain in exon 5 of DICER (Cummins
et al., 2006). As DICER is a critical enzyme involved in theassociated with PTEN 30UTR. Mean ± SD; nR 3; *p < 0.05; **p < 0.01.
le) putative PTEN ceRNAs and 25 randomly selected transcripts (bottom).
TEN ceRNAs.
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Figure 2. Coexpression of PTEN and PTEN ceRNAs in Human Cancer
(A and B) Comparison of PTEN ceRNA expression levels in primary (A) prostate cancer and (B) glioblastoma between two subsets of samples: ‘‘PTEN high’’ and
‘‘PTEN low,’’ classified according to the average PTEN expression level. p < 0.001 except for SERINC1 in glioblastoma, in which p = 0.009. The ends of the
whiskers represent the minimum and maximum of all the data.
(C) Coexpression analysis of PTEN and PTEN ceRNAs in subsets of the human prostate cancer specimens analyzed in (A) with decreased (blue, top) or increased
(red, bottom) expressionofPTEN-targetingmicroRNAs. p<0.001 for all graphs except for SERINC1microRNAup (p=0.002) andZNF460microRNAup (p=0.024).
See also Figure S2.processing of mature microRNAs, the DICEREx5 mutant cells
presented an ideal system to evaluate microRNA-dependent
effects. ThoughDICER processes the vastmajority of maturemi-
croRNAs, not all microRNAs exhibit DICER-dependent process-
ing. We thus assessed whether processing of the microRNAs
used in our analyses (Figures 1A and 1B) is abrogated in
DICEREx5 HCT116 cells. Indeed, microRNA real-time PCR anal-
ysis confirmed that these microRNAs were significantly downre-
gulated in DICEREx5 HCT116 cells (Figure S3C). We also
confirmed that siRNA-mediated gene silencing is independent348 Cell 147, 344–357, October 14, 2011 ª2011 Elsevier Inc.of DICER processing and hence is fully functional in DICEREx5
HCT116 cells (Figure S3B).
Similar to the experiments in DU145 prostate cancer cells,
siRNA-mediated depletion of SERINC1, VAPA, or CNOT6L
expression resulted in a significant downregulation of PTEN
protein in wild-type HCT116 colon cancer cells (Figures 3G
and 3H). Importantly, PTEN downregulation by ceRNA loss
was profoundly attenuated in DICEREx5 HCT116 cells (Figures
3G and 3H), suggesting that mature microRNAs are essential
for the regulation of PTEN by these three transcripts.
Figure 3. Putative PTEN ceRNAs Modulate PTEN Expression
(A) Western blot for PTEN protein levels in DU145 cells transfected with siRNA against predicted ceRNAs SERINC1 (siSER), ZNF460 (siZNF), VAPA (siVAPA), and
CNOT6L (siCNO) and selected nontargeting controls ACSL4 (siACS) and UNC5CL (siUNC).
(B) Quantitation of PTEN protein shown in (A) and PTEN mRNA changes after transfection with siRNA against ceRNA as measured by RT-PCR.
(C) Luciferase activity in DU145 cells cotransfected with siRNA against PTEN ceRNAs and a luciferase-PTEN 30UTR reporter construct.
(D) Luciferase activity in DU145 cells cotransfected with PTEN ceRNAs 30UTRs and a luciferase-PTEN 30UTR reporter construct.
(E) Western blot showing PTEN protein in response to overexpression of ceRNA 30UTRs in DU145 cells.
(F) Quantitation of PTEN protein shown in (E).
(G) Western blot for PTEN in HCT116 WT (top) and DICEREx5 (bottom) cells transfected with siRNAs against PTEN ceRNAs.
(H) Quantitation of PTEN protein shown in (G).
(B, D–F, and H) Mean ± SD; nR 4; *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S3.PTEN ceRNAs Are Regulated by PTEN-Targeting
MicroRNAs
After successfully validating SERINC1, VAPA, and CNOT6L as
bona fide PTEN ceRNAs that regulate PTEN levels in a micro-
RNA-dependent manner, we next investigated their associationwith the PTEN-targeting microRNAs used in our analysis. We
focused on VAPA and CNOT6L, as they had the most significant
effect on PTEN at the 30UTR level (Figures 3C–3F).
We constructed chimeric luciferase constructs taggedwith the
respective ceRNA 30UTR fragments. As mentioned previously,Cell 147, 344–357, October 14, 2011 ª2011 Elsevier Inc. 349
Figure 4. MicroRNA Dependency of PTEN ceRNA Function
(A) Schematic outlining the predicted binding sites of PTEN-targetingmicroRNAs to the 30UTR of VAPA. The two fragments VAPA 30UTR1 and VAPA 30UTR2were
used for the luciferase experiments.
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the VAPA and CNOT6L 30UTRs were each cloned as two sepa-
rate fragments subdivided based on the location of predicted
MREs due to their large size (Figures 4A and 4D). Expression of
miR-17, 20a, 20b, and 106a significantly reduced Luc-VAPA-
30UTR1 activity, and expression of miR-19a, 26b, and 106b
significantly reduced Luc-VAPA-30UTR2 activity in both DU145
and wild-type HCT116 cells (Figure 4B). The effect of miR-93
and 106b appeared to be cell type specific: miR-93 significantly
reduced Luc-VAPA-30UTR1 activity in HCT116 wild-type cells
only, whereas miR-106b significantly reduced Luc-VAPA-
30UTR1 activity in DU145 cells only (Figure 4B).
Consistent with the luciferase results, overexpression of
miRs 17, 19a, 20a, 20b, 26b, 106a, and 106b caused a significant
downregulation of VAPA protein levels (Figure 4C). These results
confirm that these validated PTEN-targeting microRNAs also
regulate VAPA protein levels via its 30UTR. Overexpression of
miR-93 also resulted in a significant reduction of VAPA protein
levels, in contrast to its effect on the Luc-VAPA-30UTR1 reporter.
This suggests that miR-93 is able to regulate VAPA protein levels
independently of its 30UTR, perhaps via targeting MREs located
outside of the 30UTR or modulation of upstream regulators. It is
important to note that the effects of the various microRNAs on
VAPA were consistently less profound than on those on PTEN.
This result is in agreement with the fact that VAPA transcript is
expressed at levels significantly higher than PTEN in DU145 cells
(100-fold), a factor that may significantly increase its efficacy as
a PTEN ceRNA (Figure S4A).
As predicted, miR-17, 19a, 19b, 20a, 20b, and 106b signifi-
cantly reduced Luc-CNO-30UTR1 activity in both DU145 and
wild-type HCT116 cells (Figure 4E). Transfection of miR-93
significantly reduced the activity of Luc-CNO-30UTR2, but not
Luc-CNO-30UTR1, consistent with the location of the predicted
MRE (Figure 4E). As we were unable to find a good antibody
for CNOT6L for western blot analysis, we instead performed
RIP to confirm the physical association of these microRNAs
with the CNOT6L 30UTR. RIP for CNOT6L 30UTR1 in DU145
prostate cancer cells significantly enriched for miR-17-5p, 19a,
19b, 20a, and 106b compared to empty vector and IgG controls,
whereas RIP for CNOT6L 30UTR2 significantly enriched for only
miR-93 (Figure 4F). Expression of miR-20b was not detected,
possibly due to its low level of endogenous expression (Fig-
ure S1A). These results therefore confirm the microRNA:30UTR
associations predicted by our MuTaME analysis.
Reciprocal ceRNA Interactions
Furthermore, we postulate that ceRNA networks will behave in
a mutually reciprocal manner, i.e., ceRNAs will regulate one
another bidirectionally. In an effort to study the network and(B) Luciferase activity in DU145 cells cotransfected with validated PTEN-targeting
reporter constructs.
(C) Western blot analysis of PTEN and VAPA expression in DU145 cells transfec
(D) Schematic outlining the predicted binding sites of PTEN-targeting microRNAs
were used for the luciferase and RIP experiments.
(E) Luciferase activity in DU145 cells cotransfected with validated PTEN-targetin
30UTR2 reporter constructs.
(F) RIP followed by microRNA RT-PCR shows enrichment of PTEN-targeting mic
(B, C, E, and F) Mean ± SD; nR 4; *p < 0.05; **p < 0.01; ***p < 0.001. See also Freciprocal effects of ceRNA misexpression, we investigated the
ability of PTEN downregulation to modulate VAPA protein
expression and vice versa.We could not perform this experiment
for CNOT6L due to the lack of specific antibodies, as mentioned
above. Interestingly, we observed that siRNA knockdown of
PTEN was able to significantly reduce VAPA expression in both
DU145 and HCT116 cells (Figure S4B, top and middle), thus
identifying regulatory loops between ceRNAs. This reciprocal
regulation was at least partially microRNA dependent, as it was
significantly lost in DICEREx5 HCT116 cells (Figure S4B, bottom).
Attenuated Expression of PTEN ceRNAs Activates
the PI3K/AKT Pathway
We next investigated the biological function of CNOT6L and
VAPA in accordance with defined experimental criteria (Fig-
ure 1A). On the basis of our hypothesis, the net output of any
given gene on oncogenic PI3K/AKT signaling encompasses their
protein function, as well as ceRNA effect on PTEN and other
transcripts. We therefore decided to determine which of the
PTEN ceRNAs would not solely regulate PTEN, but also yield
a robust suppressive effect on PI3K/AKT as well as on growth-
and tumor-promoting activities. First, we evaluated the conse-
quences of ceRNA-mediated PTEN regulation on the activation
of the PI3K pathway. Aberrant activation of the PI3K/AKT
pathway, at least in part, accounts for the protumorigenic effect
of PTEN loss. DU145 cells depleted of individual PTEN ceRNAs
were serum starved and restimulated, and AKT activation was
determined. Consistent with the effect on PTEN protein levels,
abrogation of CNOT6L or VAPA expression significantly elevated
phospho-Akt (p-Akt) levels in response to serum stimulation
(Figure 5A).
Depletion of CNOT6L in wild-type HCT116 augmented AKT
activation in response to serum starvation and restimulation
(1.6- and 2.1-fold change at 5 and 15 min, respectively, relative
to the negative control transfection at the same time points) (Fig-
ure 5A), similar to the effects observed in DU145 cells. Similarly,
VAPA depletion elevated p-Akt levels postrestimulation (1.8- and
2.1-fold change at 0 and 5min, respectively, relative to the nega-
tive control transfection at the same time points) (Figure 5A).
Notably, the effect of CNOT6L depletion on p-AKT was
completely abrogated in DICEREx5 HCT116 cells (p-Akt levels
at 5 and 15 min were 0.9- and 0.4-fold, respectively, relative to
the negative control transfection at the same time points), and
the effect of VAPA depletion was significantly reduced (p-Akt
levels at 0 and 5min were 0.8- and 1.4-fold, respectively, relative
to the negative control transfection at the same time points) (Fig-
ure 5A). Our results therefore demonstrate that downregulation
of CNOT6L and VAPA activated the PI3K/AKT pathway inmicroRNAs predicted to target VAPA and luciferase-VAPA-30UTR1 and 30UTR2
ted with validated PTEN-targeting microRNAs predicted to target VAPA.
to the 30UTR of CNOT6L. The two fragments CNOT 30UTR1 and CNOT 30UTR2
g microRNAs predicted to target CNOT6L and luciferase-CNOT-30UTR1 and
roRNAs associated with CNOT6L 30UTR.
igure S4.
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A B
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Figure 5. Depletion of PTEN ceRNAs Activates the PI3K/AKT Pathway and Promotes Growth In Vitro
(A) Western blot for phospho-AKT following serum starvation and restimulation of PTEN ceRNA siRNA-transfected DU145 cells (top), HCT116 WT (middle), and
DICER/ cells (bottom). Quantitation of western analyses is shown below the respective blots.
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a microRNA-dependent manner, consistent with their role as
PTEN ceRNAs.
PTEN ceRNAs Display Tumor-Suppressive Properties
AsCNOT6L and VAPA appeared to phenocopy PTEN loss-medi-
ated AKT activation based on their function as PTEN ceRNAs,
we next determined whether these ceRNAs possess tumor-
suppressive properties, as well as their status in human cancer
(Figure 1A). To address this, we first evaluated cell proliferation
and transformation in response to siRNA-mediated silencing of
these PTEN ceRNAs. Reduced expression of CNOT6L or
VAPA in cell lines where PTEN is regulated by these ceRNAs
(DU145 and HCT116) resulted in a significant increase in prolifer-
ation similar to that observed with the PTEN siRNA (Figure 5B,
top and middle). This effect on growth was significantly attenu-
ated in the DICEREx5 cells, suggesting that it is partially micro-
RNA dependent (Figure 5B, bottom). Conversely, ectopic over-
expression of 30UTRs from PTEN and its ceRNAs, CNOT6L or
VAPA, in DU145 cells led to a significant reduction in prolifera-
tion, suggesting that the observed phenotype is at least partially
coding independent (Figure 5C). Moreover, depletion of CNOT6L
or VAPA in DU145 cells promoted anchorage-independent
growth in semisolid medium (Figure 6A).
Further support for the tumor-suppressive function of
CNOT6L is provided in a Sleeping Beauty insertional mutagen-
esis screen in oncogenic BRAF-induced melanoma, which
reports that CNOT6L, along with other PTEN ceRNAs, are sub-
jected to a significant enrichment of transposon insertion sites
(Karreth et al., 2011 [this issue of Cell]). PTEN itself was one of
the most significant targets of insertion discovered in this study,
validating the ability of this approach to identify genes implicated
in human melanoma. Thus, CNOT6L dysregulation may be rele-
vant for cancer development in an in vivo mouse model.
Finally, we examined alterations of the CNOT6L and VAPA
genomic loci in human cancer. Remarkably, in a large data set
of colon cancer (GSE11417, normal n = 56, colon adenocarci-
noma n = 52) (Kurashina et al., 2008), copy number loss of both
CNOT6L (p = 3.19e6, t test = 4.926) and VAPA (p = 1.37e7,
t test =5.834)waspresent in a significant population of samples
(Figure 6B). PTEN was also significantly downregulated in this
data set (p = 1.74e4, t test = 3.810). These data demonstrate
the existence of significant copy number losses at both the
VAPA and CNOT6L genomic loci, supporting the hypothesis
that they possess tumor-suppressive properties and are under
selective pressure to undergo copy number losses in cancer.
DISCUSSION
The findings presented herein have allowed us to reach a number
of important conclusions. First, we demonstrate that protein-
coding mRNA transcripts can crosstalk with other mRNA tran-(B) Proliferation curve of DU145 cells (top), HCT116 WT (middle), and DICER
siCNOT6L, and siVAPA result in a significant increase in growth relative to the siNC
In the HCT D/ cells, siCNOT6L (p < 0.05) and siVAPA (p < 0.01) result in a sign
(C) Proliferation curve of DU145 cells transfected with plasmids overexpressing
fection, CNOT 30UTR2 (p < 0.05), VAPA 30UTR1 (p < 0.05), VAPA 30UTR2 (p < 0.
(B and C) Mean ± SD; nR 3.scripts by competing for common microRNAs, hence attributing
to protein-coding mRNA transcripts a previously unrecognized
noncoding function that is encrypted in themRNA itself. Second,
we establish that this crosstalk occurs through a language based
on MREs that allows for bioinformatic predictions toward the
definition of the ceRNA network for a given mRNA. An important
implication of our findings is that, in addition to their function as
cis regulatory elements that regulate the expression of their own
transcripts, 30UTRs are also transmodulators of gene expression
through microRNA binding. This is particularly important given
the identification of 30UTRs expressed separately from the asso-
ciated protein-coding sequences to which they are normally
linked (Mercer et al., 2011).
Third, we propose a set of defined rules and have developed
a methodology to identify, classify, and validate protein-coding
ceRNAs that can crosstalk by identifying shared MREs. We
have demonstrated that our approach can be predictive in
finding ceRNAs that can modulate PTEN through microRNA
competition. More generally, in doing so, we have identified
a unique means to rapidly identify previously uncharacterized
mRNA regulators.
Moreover, our MRE matching methodology has allowed us
to identify ceRNAs with putative tumor-suppressive function,
which is exerted, at least in part, through their ability to modulate
PTEN and the PI3K signaling output (Figure 6C). This, in turn,
functionally links a number of unexpected biological and
tumor-suppressive pathways to the proto-oncogenic PTEN/
PI3K-signaling pathway through the ceRNA noncoding language
(Figure S1C). For example, CNOT6L is a cytoplasmic deadeny-
lase that is involved in poly(A) tail shortening (Wang et al.,
2010), and vesicle-associated membrane protein-associated
protein-A (VAPA) is an integral membrane protein implicated in
transport between the endoplasmic reticulum and Golgi vesicle
(Prosser et al., 2008; Wyles et al., 2002).
These ceRNAs were not functionally linked to PTEN before
and have been now related to this critical tumor suppressor on
the sole basis of their predicted ceRNA function. We have vali-
dated this interaction by measuring the coexpression of such
ceRNAs with PTEN, determining the growth/tumor-suppressive
function of such ceRNAs, and demonstrating that the expression
of these ceRNAs and their allelic status is decreased in cancer
specimens as determined by interrogating large cancer-derived
gene expression data sets. Further validation stems from our
identification of PTEN ceRNAs, including CNOT6L, in vivo in an
oncogenic BRAF-induced mouse model of melanoma (Karreth
et al., 2011 [this issue of Cell]).
We had recently proposed that the ceRNA language would
allow RNA to communicate (Salmena et al., 2011). However, it
remained to be established whether this theory could be trans-
lated into useful predictions. In this study, we define a compre-
hensive and integrated bioinformatic and experimental/ cells (bottom) transfected with siRNAs against PTEN ceRNAs. siPTEN,
control in DU145 and HCTWT cells (p < 0.001 in DU145; p < 0.01 in HCTWT).
ificant decrease in growth relative to the siPTEN positive control.
PTEN or ceRNA 30UTRs. Relative to the empty vector control (pcDNA) trans-
001), and PTEN 30UTR (p < 0.001) result in a significant decrease in growth.
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Figure 6. VAPA and CNOT6L Possess Tumor-Suppressive Properties
(A) Anchorage-independent growth of DU145 cells transfected with siRNAs against PTEN ceRNAs in semisolid medium. Bottom panel shows quantitation of
colony formation after 10 days. Mean ± SE; nR 3; ***p < 0.001.
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approach for the prediction and validation of ceRNA activity and
networks. This approach can therefore be employed to identify
and validate ceRNAs for other mRNAs of interest. That the iden-
tification of ceRNAs is indeed possible through bioinformatic
predictions is corroborated by an accompanying study (Sumazin
et al., 2011 [this issue ofCell]). It is important to note that previous
studies have reported a trans-regulatory modulation of gene
expression through the binding of shared microRNAs, but these
studies focused mainly on the regulation of a single microRNA
(Cazalla et al., 2010; Lee et al., 2009) and of conserved ceRNAs
such as pseudogenes (Poliseno et., 2010b). This study now
extends this mechanism to potentially any mRNAs that share
MREs and thus suggests the presence of a large regulatory
network built from this extensive crosstalk among mRNAs.
Although we have focused only on protein-coding RNA, the
fact that ceRNA function does not rely on the protein-encoding
genetic blueprint that mRNA harbors within its nucleotide
sequence suggests that all MRE-containing components of the
transcriptome, including mRNAs, transcribed pseudogenes,
and long noncoding RNAs (lncRNA), are capable of regulating
each other in thismanner. This is supported by an accompanying
study in which the long noncoding RNA linc-MD1 is shown to
regulate muscle differentiation by acting as a ceRNA for muscle
differentiation factors MEF2C and MAML1 (Cesana et al., 2011,
[this issue of Cell]).
We therefore propose that the ceRNA language expands the
total collection of functional genetic information in our genome
by orders of magnitude and attributes a noncoding function to
protein-coding transcripts, which may play an important role in
physiological processes and pathological conditions (Salmena
et al., 2011). In this study, we have therefore identified an unan-
ticipated dimension by which RNA molecules can communicate
and exert their functions and a means to predict these functions
through the annotation of the ceRNA language.
EXPERIMENTAL PROCEDURES
MicroRNA Target Prediction
MicroRNA target prediction was performed using Rna22, which is available
through a graphical user interface or a batch utility at http://cbcsrv.watson.
ibm.com/rna22.html (Miranda et al., 2006).
Reagents
Reagents are as follows: anti-HSP90 antibody 61041 (Becton Dickinson); anti-
PTEN antibody 9559 (Cell Signaling); anti-VAPA antibody sc-98890 (Santa
Cruz); siGENOME siRNA reagents for nontargeting 2 (siNC), PTEN (siPTEN),
ZNF460 (siZNF), CNOT6L (siCNO), SERINC1 (siSER), VAPA (siVAPA), and
Dharmafect 1 (Dharmacon); Lipofectamine 2000, Trizol reagent, Dulbecco’s
modified Eagle medium (DMEM), Opti-MEM reduced serum media, and fetal
bovine serum (FBS) (Invitrogen); psiCHECK-2 vector and dual-luciferase
reporter assay (Promega); and RNeasy mini kit, DNeasy blood and tissue kit,
and Qiaprep spin miniprep kit (QIAGEN).
Plasmids
The 30UTRs of PTEN, CNOT6L, SERINC1, and VAPA were amplified by
PCR from the genomic DNA of DU145 cells and were cloned into pcDNA3.1+(B) Heatmap depicting the genomic status of PTEN, VAPA, and CNOT6L in human
units, p = 1.74e4, 1.37e7, and 3.19e6 for PTEN, VAPA, and CNOT6L, respect
(C) Model of regulation of PTEN expression. Posttranscriptional regulation via seq
PTEN regulation.according to standard protocols. Due to size constraints, CNOT6L and
VAPA 30UTRs were each cloned as two separate fragments. The PTEN 30UTR
was then subcloned into psiCHECK-2 using XhoI and NotI restriction sites.
PTEN 30UTR was also subcloned into the pMS2 vector for RIP analysis.
Primer sequences are as follows: PTEN30UTR-F TAGAGGAGCCGTCAAA
TCCA, PTEN30UTR-R CCCCCACTTTAGTGCACAGT, CNOT6L30UTR1-F AA
GACGGGGATCTGTTGCTA, CNOT6L30UTR1-R GGGCTCCTCTGTGGTTC
ATA, CNOT6L30UTR2-F CCACCTACTGCTCCTTGCTC, CNOT6L30UTR2-R
CTTTTGCACGCACACTTTGT, SERINC130UTR-F AGACTTCTAGCATGAAA
GTCCCACT, SERINC130UTR-R TTCATTTATTTAGAGGTAAAACACAGC,
VAPA30UTR1-F CCTTGTGAGGCAGTTGTTGA, VAPA30UTR1-R TTTTGCA
CACAAGCAAGAGG, VAPA30UTR2-F TCACCTCACTGCAGCTTCC, and
VAPA30UTR2-R TGCAAAACTTTATTTTGATTCTCG.
Cell Culture and Transfection
DU145, HCT116wild-type, and DICEREx5 cells were grown in DMEMplus 10%
FBS, penicillin/streptomycin, and glutamine at 37C in a humidified atmo-
sphere with 5% CO2. For the transfection of siRNAs, DU145 or HCT116
were transfected with 100 nM siRNAs in 12-well dishes at a density of
100,000 or 130,000 cells per well, respectively. Transfection was performed
with Dharmafect 1 according to the manufacturer’s recommendations. With
this protocol, more than 90% of cells were positive for the fluorescent siGLO
RISC-free control siRNA (data not shown). For plasmid transfection, DU145
were seeded in 12-well dishes at a density of 120,000 cells per well. Transfec-
tion was performed 24 hr later with Lipofectamine 2000 according to the
manufacturer’s recommendations. Cells were trypsinized and seeded for the
various assays 8 hr posttransfection.
Protein Extraction and Western Blot Analysis
Cells were washed in chilled PBS and lysed directly in the wells by incubating
on ice for 20 min with RIPA lysis buffer containing protease inhibitors. Lysates
were cleared by centrifugation at 4C for 15 min at 12,100 3 g, and protein
concentrations were determined using Bradford dye (Bio-Rad). For western
blot analysis, 10 mg of total protein was size fractionated by SDS-PAGE on
4%–12% Bis-Tris acrylamide NuPAGE gels in MOPS SDS running buffer
(Invitrogen) and transferred to nitrocellulosemembranes (Whatman) in NuPage
transfer buffer (Invitrogen) containing 10% methanol. The membranes were
then probed with specific primary antibodies (see ‘‘Reagents’’ in Experimental
Procedures).
RNA Extraction and Real-Time PCR
For real-time PCR analyses, total RNA was extracted from cells using Trizol
reagent as per the manufacturer’s instructions and subsequently column puri-
fiedwith RNeasy kits (QIAGEN). cDNA synthesis was performed using theHigh
Capacity cDNA Archive kit according to the manufacturer’s instructions
(Applied Biosystems). MicroRNA reverse transcription was performed with
the microRNA reverse transcription kit according to manufacturer’s instruc-
tions (Applied Biosystems). Real-time PCRwas subsequently performed using
the LightCycler 480 System (Roche Applied Science).
Luciferase Assays
MicroRNA target validation assays were performed as described previously
(Tay et al., 2008). DU145 cells were seeded 24 hr before transfection at a
density of 120,000 cells/well in 12-well plates. 100 ng of empty psiCHECK-2
vector or psiCHECK-2+PTEN30UTR was cotransfected with 100nM siRNA or
1 mg vector constructs with Lipofectamine 2000 according to manufacturer’s
instructions. In all cases, a constitutively expressed firefly luciferase gene in
psiCHECK-2 was used as a normalization control for transfection efficiency.
At 72 hr after transfection, firefly and Renilla luciferase activities were
measured consecutively with the dual-luciferase reporter system (Promega)
using a luminometer (Promega).colon adenocarcinoma compared to normal samples. Scale: log2 copy number
ively.
uestration of microRNAs by ceRNAs represents a trans-regulatory dimension of
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Cell Proliferation
At 8 hr posttransfection, DU145 cells were trypsinized, resuspended, and
seeded in four separate 12-well plates at a final density of 20,000/well. Starting
from the following day (d0), one plate per day was washed once with PBS,
fixed in 10% formalin solution for 10 min at room temperature, and then
kept in PBS at 4C. On the last day, all of the wells were stained with crystal
violet. After lysis with 10% acetic acid, optical density was read at 595 nm.Growth in Semisolid Medium
The bottom layer was obtained by covering 6-well dishes with 3 ml of 0.6%
agar in DMEM. The day after, transfected DU145 cells were seeded on top
in triplicate in 2 ml of 0.3% agar in DMEM plus 10% FBS. Colonies were
counted after 10 days at 403 magnification.RNA Immunoprecipitation and Analysis
Cells were lysed on ice 48 hr after transfection with MS2 plasmids (Kim et al.,
2009), and RIPs were performed as previously described (Keene et al., 2006).
Briefly, cell lysates were incubated overnight at 4C with control Rabbit IgG
(Jackson ImmunoResearch) or anti-YFP antibody (Santa Cruz) that were
bound to Protein A Sepharose beads (Sigma). Beads were then washed five
times with NT2 buffer, and RNA was eluted by incubation with SDS-TE buffer
by heating at 55C for 30 min. RNA was then precipitated using the standard
Trizol (Invitrogen) protocol and analyzed via real-time PCR.PTEN and ceRNA Coexpression Analysis and Genomic Status
Assessment
Coexpression in prostate cancer was evaluated using GEO super-series
GSE21032 (Taylor et al., 2010). From this data set, whole-transcript expression
data for human primary and metastatic prostate cancer samples (GSE21034)
and microRNA expression data for human primary and metastatic prostate
cancer samples (GSE21036) were analyzed. Processed and normalized
expression datawere downloaded fromNCBI. To study differential expression,
samples were subdivided into two subsets according to PTEN expression:
a PTEN-down subset with samples showing a PTEN expression level lower
than the PTEN average value calculated among all samples and a PTEN-up
subset characterized by a PTEN expression level higher than this average
value. To select subsets of samples with lower or higher microRNA expression
level, at least onemicroRNAout of tenmicroRNAs targetingPTENwas required
to show an expression level lower (or higher) than a standard deviation from its
average level; samples inwhich the different levels of expression amongmicro-
RNAs were not consistent were discarded. Thirty-three samples were thus
obtained for the subset with higher expression and 26 for that with lower
expression. Differential expression in glioblastoma was assessed by the anal-
ysis of GEO series GSE15824. Processed and normalized expression data
were downloaded from NCBI, and entrez gene ID were linked to Affymetrix
probe sets by Affymetrix annotation na31. Coexpression between PTEN and
the ceRNA genes were analyzed in multitissues, and normal tissue-specific
human-mouse conserved and human-specific coexpression networks were
generated from a specific annotated database (http://www.cbu.mbcunito.it/
ts-coexp) (Piro et al., 2011); the coexpression was considered significant
if it was found in the top 1% of the ranked list of genes coexpressed with
PTEN. Genomic status was assessed using the GEO series GSE11417 (Kura-
shina et al., 2008). Oncomine (Compendia Bioscience, Ann Arbor, MI) was
used for analysis and visualization (http://www.oncomine.org).Statistical Analysis
In vitro data were analyzed using unpaired Student’s t test. Values of p < 0.05
were considered statistically significant. *p < 0.05; **p < 0.01; ***p < 0.001. The
mean ± SD of three or more independent experiments is reported.SUPPLEMENTAL INFORMATION
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